Literature DB >> 27179556

Surgical treatment of osteonecrosis of the jaw with the use of platelet-rich fibrin: a prospective study of 15 patients.

S E Nørholt1, J Hartlev2.   

Abstract

The objective of this study was to evaluate the outcome of the surgical treatment of osteonecrosis of the jaw (ONJ) with the additional use of autologous membranes of platelet-rich fibrin (PRF). The study population consisted of 15 patients with ONJ lesions in the maxilla (n=3), mandible (n=11), or both (n=1). Eight patients had malignant disease and were treated with high-dose anti-resorptive medication; seven were treated with low-dose anti-resorptive drugs for osteoporosis. Thirteen patients had grade 2 ONJ lesions and two had grade 3 lesions. The following standardized surgical technique was applied: resection of necrotic bone, mobilization of mucoperiosteal flaps, and multiple layer coverage of bone with PRF membranes. At follow-up 7-20 months after surgery, complete mucosal healing and an absence of symptoms were found in 14 of the 15 patients (93%). The patient with persistent bone exposure had a grade 3 ONJ lesion before surgery. This study suggests that the use of PRF membranes in the surgical treatment of grade 2 ONJ may be a contributing factor to a successful outcome.
Copyright © 2016 International Association of Oral and Maxillofacial Surgeons. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Denosumab; anti-resorptive drugs; bisphosphonate-related osteonecrosis of the jaw; membranes; platelet concentrates; platelet-rich fibrin

Mesh:

Substances:

Year:  2016        PMID: 27179556     DOI: 10.1016/j.ijom.2016.04.010

Source DB:  PubMed          Journal:  Int J Oral Maxillofac Surg        ISSN: 0901-5027            Impact factor:   2.789


  10 in total

1.  The effect of concentrated growth factor (CGF) in the surgical treatment of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: a randomized controlled study.

Authors:  Meltem Ozden Yüce; Emine Adalı; Gözde Işık
Journal:  Clin Oral Investig       Date:  2021-01-03       Impact factor: 3.573

2.  Advanced platelet-rich-fibrin (A-PRF +) has no additional effect on the healing of post-extraction sockets of upper third molars. A split mouth randomized clinical trial.

Authors:  Davisson Alves Pereira; Pedro Gomes Junqueira Mendes; Nuryê Rezende Prisinoto; Gabriella Lopes de Rezende Barbosa; Priscilla Barbosa Ferreira Soares; Guilherme José Pimentel Lopes de Oliveira
Journal:  Oral Maxillofac Surg       Date:  2022-05-25

Review 3.  Is serum C-terminal telopeptide cross-link of type 1 collagen a reliable parameter for predicting the risk of medication-related osteonecrosis of the jaws? A systematic review and meta-analysis of diagnostic test accuracy.

Authors:  Bassel Traboulsi-Garet; Adrià Jorba-García; Octavi Camps-Font; Fabio Abreu Alves; Rui Figueiredo; Eduard Valmaseda-Castellón
Journal:  Clin Oral Investig       Date:  2022-02-06       Impact factor: 3.573

4.  Evaluation of advanced platelet-rich fibrin (PRF) as a bio-carrier for ampicillin/sulbactam.

Authors:  Anton Straub; Andreas Vollmer; Thiên-Trí Lâm; Roman C Brands; Maximilian Stapf; Oliver Scherf-Clavel; Max Bittrich; Andreas Fuchs; Alexander C Kübler; Stefan Hartmann
Journal:  Clin Oral Investig       Date:  2022-08-09       Impact factor: 3.606

5.  The Treatment of Medication-Related Osteonecrosis of the Jaw (MRONJ): A Systematic Review with a Pooled Analysis of Only Surgery versus Combined Protocols.

Authors:  Olga Di Fede; Federica Canepa; Vera Panzarella; Rodolfo Mauceri; Carmine Del Gaizo; Alberto Bedogni; Vittorio Fusco; Pietro Tozzo; Giuseppe Pizzo; Giuseppina Campisi; Antonio Galvano
Journal:  Int J Environ Res Public Health       Date:  2021-08-10       Impact factor: 3.390

6.  Factors Exacerbating Clinical Symptoms and CT Findings in Patients with Medication-Related Osteonecrosis of the Jaw Receiving Conservative Therapy: A Multicenter Retrospective Study of 53 Cases.

Authors:  Yuka Kojima; Sakiko Soutome; Mitsunobu Otsuru; Saki Hayashida; Yuki Sakamoto; Shunsuke Sawada; Masahiro Umeda
Journal:  Int J Environ Res Public Health       Date:  2022-06-26       Impact factor: 4.614

7.  Complementarity of surgical therapy, photobiomodulation, A-PRF and L-PRF for management of medication-related osteonecrosis of the jaw (MRONJ): an animal study.

Authors:  Mohammad Reza Jamalpour; Shiva Shahabi; Mehdi Baghestani; Abbas Shokri; Shokoofeh Jamshidi; Salman Khazaei
Journal:  BMC Oral Health       Date:  2022-06-18       Impact factor: 3.747

8.  Treatment of medication-related osteonecrosis of the jaws (MRONJ) with ultrasonic piezoelectric bone surgery. A case series of 20 treated sites.

Authors:  Cornelio Blus; Giulio Giannelli; Serge Szmukler-Moncler; Germano Orru
Journal:  Oral Maxillofac Surg       Date:  2016-12-06

9.  Mandibular Reconstruction with Free Fibula Flap for Medication-related Osteonecrosis of the Jaw in Patients with Multiple Myeloma.

Authors:  Christodoulos Kaoutzanis; Jason W Yu; Z-Hye Lee; Ashkan Davary; Kenneth E Fleisher; Jamie P Levine
Journal:  Plast Reconstr Surg Glob Open       Date:  2020-10-28

10.  Human amniotic membrane: an improvement in the treatment of Medication-related osteonecrosis of the jaw (MRONJ)? A case-control study.

Authors:  Mirko Ragazzo; Matteo Val; Giulia Montagner; Diletta Trojan; Stefano Fusetti; Luca Guarda Nardini
Journal:  Cell Tissue Bank       Date:  2021-04-15       Impact factor: 1.522

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.